Published in Adipocyte on May 07, 2013
New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int (2014) 1.24
The associations between cardiometabolic risk factors and visceral fat measured by a new dual-energy X-ray absorptiometry-derived method in lean healthy Caucasian women. Endocrine (2014) 0.85
Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia (2016) 0.85
Newborn Adipokines and Birth Outcomes. Paediatr Perinat Epidemiol (2015) 0.82
Intrauterine growth restriction increases TNF α and activates the unfolded protein response in male rat pups. J Obes (2014) 0.81
The cell size and distribution of adipocytes from subcutaneous and visceral fat is associated with type 2 diabetes mellitus in humans. Adipocyte (2015) 0.79
Does bariatric surgery improve adipose tissue function? Obes Rev (2016) 0.78
Adiponectin protects against incident hypertension independent of body fat distribution: observations from the Dallas Heart Study. Diabetes Metab Res Rev (2016) 0.76
White adipose tissue resilience to insulin deprivation and replacement. PLoS One (2014) 0.76
Two-year changes in circulating adiponectin, ectopic fat distribution and body composition in response to weight-loss diets: the POUNDS Lost Trial. Int J Obes (Lond) (2016) 0.76
Relationship of adipocyte size with adiposity and metabolic risk factors in Asian Indians. PLoS One (2014) 0.75
Maternal and cord blood adiponectin levels in relation to post-natal body size in infants in the first year of life: a prospective study. BMC Pregnancy Childbirth (2016) 0.75
Metabolically distinct weight loss by 10,12 CLA and caloric restriction highlight the importance of subcutaneous white adipose tissue for glucose homeostasis in mice. PLoS One (2017) 0.75
Oral β-hydroxybutyrate increases ketonemia, decreases visceral adipocyte volume and improves serum lipid profile in Wistar rats. Nutr Metab (Lond) (2017) 0.75
Genetic determinants of adiponectin regulation revealed by pregnancy. Obesity (Silver Spring) (2017) 0.75
Cooling reduces cAMP-stimulated exocytosis and adiponectin secretion at a Ca2+-dependent step in 3T3-L1 adipocytes. PLoS One (2015) 0.75
Comparison of Visceral Fat Accumulation and Metabolome Markers among Cats of Varying BCS and Novel Classification of Feline Obesity and Metabolic Syndrome. Front Vet Sci (2017) 0.75
Use and abuse of HOMA modeling. Diabetes Care (2004) 16.97
Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest (2007) 8.71
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev (2000) 8.15
Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia (2003) 5.91
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA (2009) 5.08
Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest (1983) 4.70
Body mass index, waist circumference, and health risk: evidence in support of current National Institutes of Health guidelines. Arch Intern Med (2002) 4.47
The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr (1956) 4.11
Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem (2003) 4.08
Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab (2006) 3.72
Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia (2000) 3.63
Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med (2000) 3.44
The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. J Clin Invest (1968) 3.11
Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care (2006) 2.77
Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes (2009) 2.60
Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol (1991) 2.56
Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord (2008) 1.95
Fat cell enlargement is an independent marker of insulin resistance and 'hyperleptinaemia'. Diabetologia (2007) 1.84
Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab (2002) 1.78
The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest (2007) 1.56
Morphological changes in the adipocyte during fat deposition and mobilization. Am J Physiol (1967) 1.46
Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells. Diabetologia (2007) 1.42
Adipose tissue adiponectin production and adiponectin serum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab (2004) 1.23
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Sex differences in regional distribution of fat cell size and lipoprotein lipase activity in morbidly obese patients. Int J Obes (1987) 1.19
Role of insulin action and cell size on protein expression patterns in adipocytes. J Biol Chem (2004) 1.17
Genetic predisposition for Type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS One (2011) 1.16
Visceral adipocyte hypertrophy is associated with dyslipidemia independent of body composition and fat distribution in women. Diabetes (2011) 1.14
Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm Metab Res Suppl (1988) 1.13
Adipose tissue dysfunction in obesity and lipodystrophy. Clin Cornerstone (2006) 1.13
Regulation of lipolysis in small and large fat cells of the same subject. J Clin Endocrinol Metab (2011) 1.12
Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia (2006) 1.11
Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring) (2008) 1.11
Fat-cell mass, serum leptin and adiponectin changes during weight gain and loss in yellow-bellied marmots (Marmota flaviventris). J Comp Physiol B (2004) 1.09
Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs (2002) 1.07
Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism (2009) 1.07
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Differential effect of weight loss on adipocyte size subfractions in patients with type 2 diabetes. Obesity (Silver Spring) (2009) 1.00
Relationships between circulating adiponectin levels and fat distribution in obese subjects. J Atheroscler Thromb (2011) 1.00
Adipose tissue fat cell size and number in relation to metabolism in randomly selected middle-aged men and women. Metabolism (1971) 0.96
Relationship of high-molecular-weight adiponectin levels to visceral fat accumulation in hemodialysis patients. Intern Med (2010) 0.87
Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation. Antiviral Res (2010) 0.83
Regional variation in HDL metabolism in human fat cells: effect of cell size. Am J Physiol (1987) 0.82
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther (2008) 1.95
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 1.85
Adiponectin in health and disease. Diabetes Obes Metab (2007) 1.64
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril (2007) 1.63
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes (2003) 1.62
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 1.44
The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects. J Pediatr (2012) 1.42
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest (2011) 1.33
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab (2013) 1.30
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract (2003) 1.26
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc (2003) 1.22
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther (2013) 1.17
Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab (2007) 1.17
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes (2002) 1.15
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radic Res (2007) 1.08
Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci (2011) 1.08
Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab (2005) 1.07
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes (2002) 1.06
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med (2010) 1.06
Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res (2005) 1.04
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care (2002) 1.03
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J Appl Physiol (1985) (2010) 0.99
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev (2006) 0.98
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol (2004) 0.98
Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep (2002) 0.98
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab (2006) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab (2005) 0.95
In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab (2010) 0.95
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab (2003) 0.94
Incretin therapies: effects beyond glycemic control. Am J Med (2009) 0.93
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol (2006) 0.93
Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One (2007) 0.92
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism (2003) 0.92
Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A (2012) 0.91
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab (2009) 0.90
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab (2008) 0.89
Enhanced insulin signaling via Shc in human breast cancer. Metabolism (2003) 0.89
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care (2012) 0.88
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab (2003) 0.88
Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care (2002) 0.88
Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep (2008) 0.87
Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cells. Endocrinology (2007) 0.86
Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am (2004) 0.86
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract (2015) 0.85
Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance. Am J Physiol Endocrinol Metab (2014) 0.85
Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab (2004) 0.85
Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J Nutr Biochem (2013) 0.83
Presidents' statement on WHO recommendation on HbA1c for diabetes diagnosis. Diabetes Res Clin Pract (2011) 0.83
Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications (2006) 0.83
Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis (2008) 0.81
Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: restorative effects of (-)-epicatechin-rich cocoa. Clin Sci (Lond) (2013) 0.81
Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond) (2012) 0.81
Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care (2014) 0.81